About Us
About Us
Our team
We are the integrated team of high professionals with expertise covering all aspects of managing and execution of international and local clinical trials, non-interventional and real world data studies. Our management team prior individual working experience in Big Pharma is up to 20 years.
Our previous long-term work in international pharmaceutical companies has given us valuable knowledge and practical skills, which we are constantly improving.
Moreover, our associates possess prior clinical and academic experience in clinical pharmacology, cardiology, respiratory diseases, emergency medicine, endocrinology, neurology, rheumatology, immunology, oncology and pediatrics.
We are committed to investing in the development and support of our personnel. We believe that our people are our strength.
Our previous long-term work in international pharmaceutical companies has given us valuable knowledge and practical skills, which we are constantly improving.
Moreover, our associates possess prior clinical and academic experience in clinical pharmacology, cardiology, respiratory diseases, emergency medicine, endocrinology, neurology, rheumatology, immunology, oncology and pediatrics.
We are committed to investing in the development and support of our personnel. We believe that our people are our strength.
Maria Nassonova
General Manager
Maria Nassonova has been ALMEDIS General Manager since 2019.
Prior to her election to this position, since 2012, as the Executive Manager of ALMEDIS, Maria was responsible for the planning, coordination and strategic aspects of our CRO business.
Prior to moving to EM position, Maria was responsible for ALMEDIS Quality Management System development and maintenance since May 2006.
Maria possesses over 5 years of experience with Novartis in the positions of Local Drug Safety Officer and Medical Adviser for CNS therapeutic area.
Prior to joining Novartis, Maria completed her Ph.D. course in the Rheumatology Department of the Moscow Medical Academy named after Setchenov. She holds an MD degree from the same institution.
Since 2015 Maria is the member of the Board of the Association of Clinical Trials Organizations (ACTO) – non-commercial organization of the companies / legal entities and clinical research community engaged in clinical trials in Russia.
Prior to her election to this position, since 2012, as the Executive Manager of ALMEDIS, Maria was responsible for the planning, coordination and strategic aspects of our CRO business.
Prior to moving to EM position, Maria was responsible for ALMEDIS Quality Management System development and maintenance since May 2006.
Maria possesses over 5 years of experience with Novartis in the positions of Local Drug Safety Officer and Medical Adviser for CNS therapeutic area.
Prior to joining Novartis, Maria completed her Ph.D. course in the Rheumatology Department of the Moscow Medical Academy named after Setchenov. She holds an MD degree from the same institution.
Since 2015 Maria is the member of the Board of the Association of Clinical Trials Organizations (ACTO) – non-commercial organization of the companies / legal entities and clinical research community engaged in clinical trials in Russia.
Maria Nassonova
General Manager
Maria Nassonova has been ALMEDIS General Manager since 2019.
Prior to her election to this position, since 2012, as the Executive Manager of ALMEDIS, Maria was responsible for the planning, coordination and strategic aspects of our CRO business.
Prior to moving to EM position, Maria was responsible for ALMEDIS Quality Management System development and maintenance since May 2006.
Maria possesses over 5 years of experience with Novartis in the positions of Local Drug Safety Officer and Medical Adviser for CNS therapeutic area.
Prior to joining Novartis, Maria completed her Ph.D. course in the Rheumatology Department of the Moscow Medical Academy named after Setchenov. She holds an MD degree from the same institution.
Prior to her election to this position, since 2012, as the Executive Manager of ALMEDIS, Maria was responsible for the planning, coordination and strategic aspects of our CRO business.
Prior to moving to EM position, Maria was responsible for ALMEDIS Quality Management System development and maintenance since May 2006.
Maria possesses over 5 years of experience with Novartis in the positions of Local Drug Safety Officer and Medical Adviser for CNS therapeutic area.
Prior to joining Novartis, Maria completed her Ph.D. course in the Rheumatology Department of the Moscow Medical Academy named after Setchenov. She holds an MD degree from the same institution.
Since 2015 Maria is the member of the Association of Clinical Trials Organizations (ACTO) – non-commercial organization of the companies / legal entities and clinical research community engaged in clinical trials in Russia.
Anna Torubarova
Medical Affairs Head
Anna Torubarova oversees medical affairs activities including medical writing, data management and biostatistics in ALMEDIS since May 2006.
Anna has 20 years of experience in the pharmaceutical industry, with a broad range of expertise in the development and support of new products in different TAs.
Prior to joining ALMEDIS, Anna during 6 years held a position of Medical Adviser in Novartis, Russia.
Prior to her career in the pharma industry, Anna gained 5 years of lecturing experience in computer methods in medicine in the Russian State Medical University of Moscow.
Anna has 20 years of experience in the pharmaceutical industry, with a broad range of expertise in the development and support of new products in different TAs.
Prior to joining ALMEDIS, Anna during 6 years held a position of Medical Adviser in Novartis, Russia.
Prior to her career in the pharma industry, Anna gained 5 years of lecturing experience in computer methods in medicine in the Russian State Medical University of Moscow.
Anna Torubarova holds an MD and a PhD in Public Health from the Russian State Medical University of Moscow.
Anna Torubarova
Medical Affairs Head
Anna Torubarova oversees medical affairs activities including medical writing, data management and biostatistics in ALMEDIS since May 2006.
Anna has 20 years of experience in the pharmaceutical industry, with a broad range of expertise in the development and support of new products in different TAs.
Prior to joining ALMEDIS, Anna during 6 years held a position of Medical Adviser in Novartis, Russia.
Prior to her career in the pharma industry, Anna gained 5 years of lecturing experience in computer methods in medicine in the Russian State Medical University of Moscow.
Anna has 20 years of experience in the pharmaceutical industry, with a broad range of expertise in the development and support of new products in different TAs.
Prior to joining ALMEDIS, Anna during 6 years held a position of Medical Adviser in Novartis, Russia.
Prior to her career in the pharma industry, Anna gained 5 years of lecturing experience in computer methods in medicine in the Russian State Medical University of Moscow.
Anna Torubarova holds an MD and a PhD in Public Health from the Russian State Medical University of Moscow.
Elena Akimova
Clinical Operations Head
Elena Akimova has been the Head of the Clinical Operational Department since 2018 and is responsible for all organizational tasks when planning and conducting clinical, pharmacokinetic and observational studies at ALMEDIS.
Prior to that, Elena had been managing projects at ALMEDIS for 6 years, gaining experience in conducting research in such therapeutic areas as oncology, infectious diseases, endocrinology, pulmonology, neurology, urology, gynecology, etc.
Elena began her career in the pharmaceutical industry as a clinical research associate.
Prior to that, Elena had been managing projects at ALMEDIS for 6 years, gaining experience in conducting research in such therapeutic areas as oncology, infectious diseases, endocrinology, pulmonology, neurology, urology, gynecology, etc.
Elena began her career in the pharmaceutical industry as a clinical research associate.
Elena has a degree in Medical Biochemistry, obtained at the Russian State Medical University, and an MBA degree from Moscow Business School.
Elena Akimova
Clinical Operations Head
Elena Akimova has been the Head of the Clinical Operational Department since 2018 and is responsible for all organizational tasks when planning and conducting clinical, pharmacokinetic and observational studies at ALMEDIS.
Prior to that, Elena had been managing projects at ALMEDIS for 6 years, gaining experience in conducting research in such therapeutic areas as oncology, infectious diseases, endocrinology, pulmonology, neurology, urology, gynecology, etc.
Elena began her career in the pharmaceutical industry as a clinical research associate.
Prior to that, Elena had been managing projects at ALMEDIS for 6 years, gaining experience in conducting research in such therapeutic areas as oncology, infectious diseases, endocrinology, pulmonology, neurology, urology, gynecology, etc.
Elena began her career in the pharmaceutical industry as a clinical research associate.
Elena has a degree in Medical Biochemistry, obtained at the Russian State Medical University, and an MBA degree from Moscow Business School.
Mission
To meet patients’ needs and improve their quality of life by investing our knowledge and experience into new pharmaceutical products development through providing cost-effective and high quality services to pharmaceutical companies.
Facts about ALMEDIS
ALMEDIS has been a member of the Association of Clinical Trial Organizations (ACTO) since 2008 participating actively in its work.
In 2021 ALMEDIS marks the fifteen years of successful collaboration with a leading international Life Sciences technology provider Ennov.
In Russia ALMEDIS was the first SAS local subscriber for clinical trials (see SAS web-page for more information). Using SAS since 2009, ALMEDIS has been successfully conducting studies for many customers, including projects for half of the Top-10 international pharmaceutical companies operating in Russia.
Since 2007 ALMEDIS has been an official subscriber of MedDRA - an international dictionary of standardized medical terminology which we work with in the field of data management and pharmacovigilance.
In 2018-2019, ALMEDIS participated in the translation of MedDRA into Russian, contributing to the implementation of standard coding processes in the practice of pharmacovigilance and clinical trials in Russia.
In 2021 ALMEDIS marks the fifteen years of successful collaboration with a leading international Life Sciences technology provider Ennov.
In Russia ALMEDIS was the first SAS local subscriber for clinical trials (see SAS web-page for more information). Using SAS since 2009, ALMEDIS has been successfully conducting studies for many customers, including projects for half of the Top-10 international pharmaceutical companies operating in Russia.
Since 2007 ALMEDIS has been an official subscriber of MedDRA - an international dictionary of standardized medical terminology which we work with in the field of data management and pharmacovigilance.
In 2018-2019, ALMEDIS participated in the translation of MedDRA into Russian, contributing to the implementation of standard coding processes in the practice of pharmacovigilance and clinical trials in Russia.